Thus, we retrospectively examined BCR-ABL1 evolution in 305 chronic-phase CML patients receiving imatinib mesylate (IM) as a first line treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.